Item 1.01 Entry into a Material Definitive Agreement.
On November 15, 2022 (the "Effective Date"), Invivyd, Inc. (the "Company")
entered into a Master Services Agreement with Population Health Partners, L.P.
("PHP"), pursuant to which PHP agreed to provide services and create
deliverables for the Company as agreed between the Company and PHP and set forth
in one or more work orders under such agreement (the "MSA"). The term of the MSA
commenced on the Effective Date and will continue for a period of one year,
unless terminated earlier in accordance with its terms. On the Effective Date,
the Company and PHP entered into the first work order under the MSA (the "Work
Order"), pursuant to which PHP agreed to advise and counsel the Company
regarding clinical development and regulatory matters with respect to the
Company's product candidates, including NVD200. The Work Order is effective for
six months from the Effective Date and may be extended by written agreement of
the Company and PHP. The MSA contains customary confidentiality provisions and
representations and warranties of the parties, as well as mutual
non-solicitation of certain employees during the term of the MSA and for a
period of one year thereafter.
As compensation for the services and deliverables under the Work Order, the
Company shall pay PHP a cash fee of $500,000 per month during the term of the
Work Order for an aggregate fee of $3,000,000 (the "Aggregate Fee"). In the
event that (i) the Company terminates the Work Order for any reason other than
material breach by PHP or (ii) PHP terminates the Work Order due to material
breach by the Company, in each case, pursuant to the terms of the MSA, then the
Company would be required to pay PHP the balance of the Aggregate Fee as of the
date the Work Order is terminated. The cash fee is subject to change if the
parties extend the term of the Work Order in accordance with the terms thereof.
In addition to the cash compensation, on the Effective Date, the Company issued
a warrant to purchase shares of common stock, par value $0.0001 per share, of
the Company (the "Common Stock") to PHP (the "Warrant"). The exercise price of
the Warrant is $3.48 per share of Common Stock, which is equal to the Nasdaq
Official Closing Price of a share of Common Stock on the trading day immediately
prior to the Effective Date. The Warrant is exercisable for up to an aggregate
of 6,824,712 shares of Common Stock, and vests in three separate tranches as
• 3,591,954 shares of Common Stock underlying the Warrant vests if the
Company's Market Capitalization (as defined below) equals or exceeds
$758,517,511.00 by November 15, 2028;
• 1,795,977 shares of Common Stock underlying the Warrant vests if the
Company's Market Capitalization equals or exceeds $1,137,776,266.00 by
November 15, 2029; and
• 1,436,781 shares of Common Stock underlying the Warrant vests if the
Company's Market Capitalization equals or exceeds $1,517,035,022.00 by
November 15, 2030.
For purposes of the Warrant, the term "Market Capitalization" means, with
respect to a particular trading day, the total value of the outstanding shares
of Common Stock on such date, calculated by multiplying the Company's volume
weighted average price for the ten (10) trading days immediately preceding such
date by the Company's total number of outstanding shares of Common Stock as
reflected in (i) the Company's most recent periodic or annual report filed with
the U.S. Securities and Exchange Commission ("SEC") (e.g., Annual Report on Form
10-K or Quarterly Report on Form 10-Q), as the case may be, (ii) a more recent
public announcement by the Company or (iii) a more recent written notice by the
Company or the Company's transfer agent setting forth the number of shares of
Common Stock outstanding.
The Warrant is exercisable for ten years from the Effective Date with respect to
the vested portion(s) of the Warrant. The Warrant may be exercised by cash
exercise or, at the election of PHP, by means of "cashless exercise" pursuant to
a formula set forth in the Warrant. The Company has also granted PHP certain
"piggyback" registration rights requiring the Company to register any shares of
Common Stock underlying the Warrant for resale with the SEC, subject to the
Company's existing obligations under that certain Second Amended and Restated
Investors' Rights Agreement, dated April 16, 2021, by and among the Company and
the investors party thereto.
Upon the consummation of a change of control of the Company (as defined in the
Warrant) on or prior to November 15, 2028, all of the shares underlying the
Warrant would become immediately vested and exercisable; upon the consummation
of a change of control of the Company after November 15, 2028 but on or prior to
November 15, 2029, the shares underlying the second and third tranches of the
Warrant would become immediately vested and exercisable; and upon the
consummation of a change of control of the Company after November 15, 2029 but
on or prior to November 15, 2030, the shares underlying the third tranche of the
Warrant would become immediately vested and exercisable.
Clive Meanwell, M.D. and Tamsin Berry, members of the Company's Board of
Directors, are Managing Partner and Partner of PHP, respectively.
The description of the MSA, the Work Order and the Warrant does not purport to
be complete and is qualified in its entirety by reference to the complete text
of the MSA, the Work Order and the Warrant, respectively, each of which will be
filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal
year ending December 31, 2022.
Item 3.02. Unregistered Sales of Equity Securities
The information regarding the Warrant and the shares of Common Stock issuable
upon the exercise thereof included under Item 1.01 of this Current Report on
Form 8-K is incorporated herein by reference.
The Warrant and the shares of Common Stock issuable upon exercise thereof are
being offered and sold without registration under the Securities Act of 1933, as
amended (the "Securities Act"), pursuant to the exemption provided by
Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder as
transactions not involving a public offering, as well as similar exemptions
under applicable state securities laws, in reliance upon the following facts: no
general solicitation was used in the offer or sale of such securities; the
recipient of the securities had adequate access to information about the
Company; the recipient of such securities represented its acquisition thereof as
principal for its own account and its lack of any arrangements or understandings
regarding the distribution of such securities; the recipient of such securities
represented its capability of evaluating the merits of an investment in the
Company's securities due to its knowledge, sophistication and experience in
business and financial matters; and such securities were issued as restricted
securities with restricted legends referring to the Securities Act. No such
securities may be offered or sold in the United States in the absence of an
effective registration statement or exemption from applicable registration
requirements. No statement in this document or the attached exhibits is an offer
to purchase or sell or a solicitation of an offer to sell or buy the Company's
securities, and no offer, solicitation or sale will be made in any jurisdiction
in which such offer, solicitation or sale is unlawful.
Item 8.01. Other Events.
On November 17, 2022, the Company issued a press release announcing the
partnership with PHP. A copy of the press release is filed herewith as Exhibit
99.1 and is incorporated by reference in this Item 8.01.
Item 9.01. Financial Statements and Exhibits.
99.1 Press Release, dated November 17, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source Glimpses